Comparable stake leader
Loewenbaum Lilian S.
SEC ownership of CollPlant Biotechnologies Ltd
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001631487.
Disclosed value leader
Hugh M. Evans
Comparable rows
3/29
Latest evidence
03 Sep 2026
- Public ticker
- CLGN on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Loewenbaum Lilian S.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
3 of 29
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Loewenbaum Lilian S.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
03 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001631487
- Issuer location
- Rehovot, Israel
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of CollPlant Biotechnologies Ltd (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Loewenbaum Lilian S.
Disclosed value leader
Hugh M. Evans
Comparable rows
3/29
Latest evidence
03 Sep 2026
13D/G
13F
3/4/5
Lead comparable stake: 18%
26 rows are not safely comparable across share classes.
13D/G row: Loewenbaum Lilian S.
Showing 1-8 of 29 holder rows.
Quick read
Loewenbaum Lilian S. leads the comparable SEC ownership view at 18%.
3 of 29 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Loewenbaum Lilian S.'s linked filing trail.
Comparable ownership
Top 3
Loewenbaum Lilian S.
18%
Ami Sagy
13%
Parallel Advisors, LLC
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 29 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Loewenbaum Lilian S. |
13D/G
The Loewenbaum 1992 Trust
|
18%
|
—
3,597,047 shares
|
-$724,541 | 19 Aug 2026 |
| Ami Sagy |
13D/G
|
13%
|
—
1,637,086 shares
|
$0 | 19 Nov 2025 |
| Parallel Advisors, LLC |
13F
Company
|
0%
|
$25
71 shares
|
— | 30 Jun 2026 |
| Hugh M. Evans |
3/4/5
Director
|
—
mixed-class rows
|
$462,841
340,554 shares
mixed-class rows
|
— | 18 Mar 2026 |
| PINNACLE ASSOCIATES LTD |
13F
Company
|
—
class O/S missing
|
$255,277
731,663 shares
|
— | 30 Jun 2026 |
| VILLERE ST DENIS J & CO LLC |
13F
Company
|
—
class O/S missing
|
$211,572
606,400 shares
|
— | 30 Jun 2026 |
| Eran Rotem |
3/4/5
Deputy CEO and CFO
|
—
mixed-class rows
|
$181,814
576,372 shares
mixed-class rows
|
— | 03 Sep 2026 |
| Bar Berta Abelis |
3/4/5
VP Legal
|
—
mixed-class rows
|
$72,687
246,441 shares
mixed-class rows
|
— | 03 Sep 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 13 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to CollPlant Biotechnologies Ltd. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
Hugh M. Evans
Net 12M change
$0
Latest report
03 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Hugh M. Evans | Director | $462,841 | Mixed | 18 Mar 2026 | ||
| Eran Rotem | Deputy CEO and CFO | $181,814 | Median | 03 Sep 2026 | ||
| Bar Berta Abelis | VP Legal | $72,687 | Median | 03 Sep 2026 | ||
| Yehiel Tal | Chief Executive Officer, Director | $43,598 | Mixed | 19 Mar 2026 | ||
| Philippe Bensimon | VP Regulations and QA | $2,800 | Mixed | 18 Mar 2026 | ||
| Bowman Bagley | VP Commercial North America | Mixed | 18 Mar 2026 | |||
| Avraham Havron | Director | Mixed | 18 Mar 2026 | |||
| Alisa Lask | Director | Mixed | 18 Mar 2026 | |||
| Oren Fahimipoor | VP Operations | Mixed | 18 Mar 2026 | |||
| Elan Penn | Director | Mixed | 18 Mar 2026 | |||
| Jasmine Seror | VP Product Development | Mixed | 18 Mar 2026 |
Recent insider transactions for CollPlant Biotechnologies Ltd
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Eran Rotem | CLGN | Ordinary Shares | Award | 8506.2% | 510,372 | 516,372 | 03 Sep 2026 | Direct | ||
| Bar Berta Abelis | CLGN | Ordinary Shares | Award | 3795.1% | 201,141 | 206,441 | 03 Sep 2026 | Direct |
* marks a reported price that did not pass the local price check.